{"DataElement":{"publicId":"7150228","version":"2","preferredName":"Myeloproliferative Neoplasm Disease or Disorder Classification Type","preferredDefinition":"A description of the myeloproliferative neoplasm disease or disorder classification.","longName":"7150163v1.00:7150060v1.10","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7150163","version":"1","preferredName":"Myeloproliferative Neoplasm Disease or Disorder Classification","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"2595679v1.0:2321361v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2595679","version":"1","preferredName":"Chronic Myeloproliferative Disorder Diseases and Disorders","preferredDefinition":"Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages.  The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood.  CMPDs are primarily diseases of adults.  -- 2003:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C4345:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"294DEAFB-4E58-00B9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-12","modifiedBy":"ONEDATA","dateModified":"2007-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D223DC2-B379-6F4A-E053-F662850A686B","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"MALUMK","dateModified":"2020-12-03","changeDescription":"Released. 12/03/2020 KMM; Released. 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7150060","version":"1.1","preferredName":"Myeloproliferative Neoplasm Classification Type","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008) ._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics._Type; a subdivision of a particular kind of thing.","longName":"7150060v1.10","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Mast cell sarcoma (MCS)","valueDescription":"Mast Cell Sarcoma","ValueMeaning":{"publicId":"2838602","version":"1","preferredName":"Mast Cell Sarcoma","longName":"2838602","preferredDefinition":"A rare entity characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells.(WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Sarcoma","conceptCode":"C9348","definition":"A rare malignant neoplasm characterized by localized but destructive growth of a tumor consisting of highly atypical, immature mast cells. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE34-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DE9A-6C4C-E063-731AD00A83BF","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Systemic mastocytosis","valueDescription":"Systemic Mastocytosis","ValueMeaning":{"publicId":"3211467","version":"1","preferredName":"Systemic Mastocytosis","longName":"3211467","preferredDefinition":"A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Systemic Mastocytosis","conceptCode":"C9235","definition":"Systemic infiltration of extracutaneous sites by clonal mast cells, with or without evidence of skin involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E162-022B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DE9B-6C4C-E063-731AD00A83BF","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Cutaneous mastocytosis (CM)","valueDescription":"CUTANEOUS MASTOCYTOSIS","ValueMeaning":{"publicId":"2558582","version":"1","preferredName":"CUTANEOUS MASTOCYTOSIS","longName":"2558582","preferredDefinition":"A form of mastocytosis characterized by mast cell infiltration of the skin.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cutaneous Mastocytosis","conceptCode":"C7137","definition":"A form of mastocytosis characterized by mast cell infiltration of the skin.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B1E3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"COOPERM","dateModified":"2020-04-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DE9C-6C4C-E063-731AD00A83BF","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Chronic eosinophilic leukemia, not otherwise specified","valueDescription":"Chronic Eosinophilic Leukemia","ValueMeaning":{"publicId":"2738445","version":"1","preferredName":"Chronic Eosinophilic Leukemia","longName":"2738445","preferredDefinition":"A rare chronic myeloproliferative disorder characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","conceptCode":"C4563","definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49BDA45E-ED4F-65D3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DE9D-6C4C-E063-731AD00A83BF","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Essential thrombocythemia","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DE9E-6C4C-E063-731AD00A83BF","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Primary myelofibrosis (PMF)","valueDescription":"Primary Myelofibrosis","ValueMeaning":{"publicId":"3323718","version":"1","preferredName":"Primary Myelofibrosis","longName":"3323718","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B381BEF5-8290-6627-E040-BB89AD4359F7","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-07","modifiedBy":"ONEDATA","dateModified":"2011-12-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DE9F-6C4C-E063-731AD00A83BF","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Chronic neutrophilic leukemia","valueDescription":"Chronic Neutrophilic Leukemia","ValueMeaning":{"publicId":"2837958","version":"1","preferredName":"Chronic Neutrophilic Leukemia","longName":"2837958","preferredDefinition":"A rare chronic myeloproliferative disorder characterised by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Neutrophilic Leukemia","conceptCode":"C3179","definition":"A rare chronic myeloproliferative neoplasm characterized by neutrophilic leukocytosis.  There is no detectable Philadelphia chromosome or BCR/ABL fusion gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CECC-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA0-6C4C-E063-731AD00A83BF","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with FGFR1 rearrangement","valueDescription":"Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement","ValueMeaning":{"publicId":"6037341","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with FGFR1 Rearrangement","longName":"6037341","preferredDefinition":"Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement","conceptCode":"C84277","definition":"Hematologic neoplasms characterized by the rearrangement of the FGFR1 gene, resulting in translocations with an 8p11 breakpoint. Patients present with a myeloproliferative neoplasm, acute myeloid leukemia, lymphoblastic lymphoma/leukemia of T or B-cell lineage, or acute leukemia of mixed phenotype.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4F0B-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA1-6C4C-E063-731AD00A83BF","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with PCM1-JAK2","valueDescription":"Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2","ValueMeaning":{"publicId":"6037339","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with t(8;9)(p22;p24.1);PCM1-JAK2","longName":"6037339","preferredDefinition":"Rare myeloid neoplasms characterized by eosinophilia, bone marrow findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis, and the detection of t(8;9)(p22;p24.1) and PCM1-JAK2 fusion gene. Rare cases present as T- or B-acute lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with JAK2 Rearrangement","conceptCode":"C129853","definition":"Hematologic neoplasms characterized by the presence of t(8;9)(p22;p24.1) that results in PCM1-JAK2 fusion gene expression. It is associated with eosinophilia, bone marrow findings of left-shifted erythroid predominance, lymphoid aggregates, and often myelofibrosis. Rare cases present as T- or B-acute lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4EE5-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA2-6C4C-E063-731AD00A83BF","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with PDGFRA rearrangement","valueDescription":"Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement","ValueMeaning":{"publicId":"6037345","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with PDGFRA Rearrangement","longName":"6037345","preferredDefinition":"Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with PDGFRA Rearrangement","conceptCode":"C84275","definition":"Hematologic neoplasms characterized by the rearrangement of the PDGFRA gene, most often resulting in the formation of FIP1L1-PDGFRA fusion transcripts. Patients usually present with chronic eosinophilic leukemia, and less often with acute myeloid leukemia or T-lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4F57-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA3-6C4C-E063-731AD00A83BF","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myeloid / lymphoid neoplasms with PDGFRB rearrangement","valueDescription":"Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement","ValueMeaning":{"publicId":"6037343","version":"1","preferredName":"Myeloid and Lymphoid Neoplasms with PDGFRB Rearrangement","longName":"6037343","preferredDefinition":"Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloid/Lymphoid Neoplasms with PDGFRB Rearrangement","conceptCode":"C84276","definition":"Myeloid and rarely lymphoid neoplasms characterized by the rearrangement of the PDGFRB gene, most often resulting in the formation of ETV6-PDGFRB fusion transcripts. Patients usually present with chronic myelomonocytic leukemia and less often with atypical chronic myeloid leukemia, or chronic eosinophilic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F9DAF93-4F31-0A93-E053-F662850A5D30","latestVersionIndicator":"Yes","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA4-6C4C-E063-731AD00A83BF","beginDate":"2017-12-05","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Myeloproliferative neoplasm (MPN), unclassifiable","valueDescription":"Chronic Myeloproliferative Disease, Unclassifiable","ValueMeaning":{"publicId":"3249791","version":"1","preferredName":"Chronic Myeloproliferative Disease, Unclassifiable","longName":"3249791","preferredDefinition":"This subgroup of chronic myeloproliferative disorders includes cases which do not meet the morphologic criteria of any of the defined chronic myeloproliferative disorders, or which have characteristics that overlap at least two of the chronic myeloproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm, Not Otherwise Specified","conceptCode":"C27350","definition":"This subgroup of myeloproliferative neoplasms includes cases which do not meet the morphologic criteria of any of the defined myeloproliferative neoplasms, or which have characteristics that overlap at least two of the myeloproliferative neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DC37F6-CFCC-75B6-E040-BB89AD430517","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA5-6C4C-E063-731AD00A83BF","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"},{"value":"Polycythemia vera (PCV)","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2559822","version":"1","preferredName":"Polycythemia Vera","longName":"2559822","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA6-6C4C-E063-731AD00A83BF","beginDate":"2008-03-31","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","deletedIndicator":"No"},{"value":"Transformed to AML","valueDescription":"Conversion Acute Myeloid Leukemia","ValueMeaning":{"publicId":"3927451","version":"1","preferredName":"Conversion Acute Myeloid Leukemia","longName":"3927451","preferredDefinition":"The act of changing the nature, form, function, or purpose of something to another.: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Conversion","conceptCode":"C52566","definition":"The act of changing the nature, form, function, or purpose of something to another.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E96A8E65-4091-B964-E040-BB89AD437DDF","latestVersionIndicator":"Yes","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0F15EC27-DEA7-6C4C-E063-731AD00A83BF","beginDate":"2013-10-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"ONEDATA","dateModified":"2024-01-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7150059","version":"1","preferredName":"Myeloproliferative Neoplasm Classification Type","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4345:C25161:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D21CF6E-979A-46A7-E053-F662850A6269","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-27","modifiedBy":"ONEDATA","dateModified":"2020-01-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F15EC2B-FC67-6C3B-E063-731AD00A69C4","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-17","changeDescription":".Released 11/11/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_MPN_mpn_class_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the myeloproliferative neoplasm disease or disorder classification?","url":null,"context":"NHLBI"},{"name":"What was the MPN subtype at diagnosis?","type":"Alternate Question Text","description":"What was the MPN subtype at diagnosis?","url":null,"context":"NHLBI"},{"name":"What was the MPN subtype?","type":"Application Standard Question Text","description":"What was the MPN subtype?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT MOD","registrationStatus":"Application","id":"0F1736B0-5912-390E-E063-731AD00A961B","latestVersionIndicator":"Yes","beginDate":"2020-01-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-16","modifiedBy":"KUMMEROA","dateModified":"2024-01-16","changeDescription":"Released. 11/11/2020 KMM; System generated def displayed as alt def.","administrativeNotes":"2024.1.16 Created per ticket request CADSR0003263. ak","unresolvedIssues":null,"deletedIndicator":"No"}}